Medpace (NASDAQ:MEDP) Price Target Lowered to $477.00 at Robert W. Baird

Medpace (NASDAQ:MEDP) had its price objective reduced by Robert W. Baird from $565.00 to $477.00 in a report released on Friday morning, MarketBeat.com reports. They currently have an outperform rating on the stock.

MEDP has been the topic of several other research reports. Barclays reduced their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Leerink Partners decreased their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research note on Wednesday, February 11th. Royal Bank Of Canada started coverage on Medpace in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 price target for the company. Finally, Truist Financial cut their price target on Medpace from $555.00 to $539.00 and set a “hold” rating for the company in a research note on Wednesday, February 11th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus target price of $467.08.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $410.54 on Friday. The company has a market capitalization of $11.73 billion, a P/E ratio of 25.80, a P/E/G ratio of 1.85 and a beta of 1.39. Medpace has a 1 year low of $284.10 and a 1 year high of $628.92. The business’s 50 day simple moving average is $470.61 and its 200 day simple moving average is $535.72.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same period in the prior year, the company earned $3.67 earnings per share. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, sell-side analysts anticipate that Medpace will post 17.05 EPS for the current fiscal year.

Insider Activity

In related news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Cibc World Market Inc. purchased a new stake in Medpace in the 3rd quarter valued at about $5,033,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Medpace by 150.0% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares in the last quarter. Capital Fund Management S.A. raised its holdings in shares of Medpace by 129.5% in the 3rd quarter. Capital Fund Management S.A. now owns 32,412 shares of the company’s stock valued at $16,665,000 after purchasing an additional 18,287 shares in the last quarter. Dorsey Wright & Associates bought a new stake in shares of Medpace in the 3rd quarter valued at about $5,082,000. Finally, Baillie Gifford & Co. raised its holdings in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat and raised outlook — Medpace reported Q1 EPS of $4.28 and revenue of $706.6M, both above consensus, and gave FY2026 EPS guidance of $16.68–$17.50. Strong revenue growth and guidance are the primary bullish catalyst. Article Title
• Positive Sentiment: Analyst support remains — Robert W. Baird kept an Outperform rating with a $477 target (still implying upside), providing some analyst backing despite volatility. Article Title
• Positive Sentiment: Technical/buy‑the‑dip narratives — Some outlets note MEDP moved into oversold territory after recent selling, which can attract short‑term bargain hunters. Article Title
• Neutral Sentiment: Short‑interest data unclear — April short‑interest reporting shows effectively 0 days to cover based on the provided figure, an anomalous data point that appears neutral until clarified by exchanges/brokers.
• Neutral Sentiment: Backlog conversion but rising cancellations — Management highlighted roughly $1.94B of backlog conversion over 12 months, but cancellation rates have increased; this is a mixed operational signal that could either load revenue or indicate instability in bookings. Article Title
• Negative Sentiment: Multiple securities‑fraud class action notices filed and law‑firm solicitations — Several firms have announced lawsuits and are soliciting lead‑plaintiff motions with a June 8, 2026 deadline, increasing legal and investor‑sentiment risk. This is a material near‑term overhang. Article Title
• Negative Sentiment: Analyst caution and downgrades tied to cancellations/elevated costs — Some analysts cut stance or reduced price targets citing the spike in backlog cancellations and higher direct costs (e.g., Seeking Alpha coverage and a BMO price‑target cut to $400), which can pressure sentiment and valuation. Article Title
• Negative Sentiment: Executive departure — Medpace’s president announced his resignation after 18 years, adding leadership transition risk at a sensitive time. Article Title

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.